VJHemOnc is committed to improving our service to you

MDS 2020 | HMAs are the standard, what are their limitations?

VJHemOnc is committed to improving our service to you

Alan List

Alan List, MD, Tampa, FL, discusses the use of hypomethylating agents (HMAs) in the treatment of myelodysplastic syndromes (MDS), their limitations and how trials are seeking to diminish this unmet need. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter